Natixis’s Oric Pharmaceuticals ORIC Stock Holding History

Natixis’s Portfolio ORIC Stock Details ORIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-79,900	Closed	-$645K	–	1144
2024 Q4	$645K	Buy	+79,900	New	+$733K	﹤0.01%	667

Other funds holding ORIC

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Pfizer New York $170M AUM 191.09% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return

Column Group San Francisco, California $88.1M AUM 148.03% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Natixis's ORIC Position: Q1 2025 in Review

Natixis sold out of Oric Pharmaceuticals (ORIC) in Q1 2025, closing a stake of 79,900 shares — an estimated $645K sold.

Natixis first reported a position in ORIC in Q4 2024 and held it in 1 quarter. The position peaked at $645K in Q4 2024. 143 funds tracked by Wall St. Rank hold ORIC as of Q1 2025.

Natixis reported no remaining Oric Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Natixis sold 79,900 Oric Pharmaceuticals shares in Q1 2025, an estimated $645K.
Natixis first reported a position in Oric Pharmaceuticals in Q4 2024 and held it in 1 quarter.
Natixis's Oric Pharmaceuticals position peaked at $645K in Q4 2024.
143 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q1 2025.

Based on Natixis's 13F filing for Q1 2025, filed 14 May 2025.